Company Categories: Assays, Cell Line Development, Drug Development, Drug Discovery, Laboratory Equipment and Preclinical Toxicology
Cell-based In Vitro Assays for Drug Discovery
DetailsReadyCell is a leading manufacturer and distributor of ready-to-use Cell-based plates for In Vitro Assays in drug discovery. The company’s cutting-edge solutions are designed to support researchers’ day-to-day in vitro ADME (absorption, distribution, metabolism and excretion) and drug-induced toxicity needs.
ReadyCell’s products are developed for researchers and scientists, both in the corporate and academic fields, to support the pharmacological evaluation of drug candidates, minimise costs, facilitate lead optimization, and accelerate preclinical research and drug discovery.
Novel Tools for In Vitro Drug Discovery
ReadyCell’s suite of ready-to-use Cell-Based In Vitro Assays markedly enhances the cost-effectiveness of drug discovery efforts by streamlining the lead optimization process and expediting the drug discovery timeline. The company’s cell plates feature a novel patented gel-like medium, allowing cells to be shipped at room temperature without losing quality or function, helping researchers achieve optimal results.
The ReadyCell products include critical assays for adsorption, metabolism, and toxicity, guaranteeing robust and regulatory-compliant drug development processes. By simplifying workflows, reducing the need for animal testing and ensuring the swift progression of promising compounds to the clinical trial phase, researchers can save valuable time and resources.
In Vitro ADME and Toxicology Assays
ReadyCell provides innovative products to address a wide spectrum of in vitro ADME-Tox requirements. The company offers a range of high-quality cell kits specifically designed to assess the permeability, toxicity, and transport of drugs across biological barriers, such as the intestinal epithelium or the blood-brain barrier.
The tools are pre-plated with a proprietary gel-like medium which guarantees superior cell quality within the plates to expedite different in vitro drug discovery applications.
In Vitro Permeability Assays
ReadyCell offers Pre-plated Permeability Assays with Caco-2, HT-29, and MDCKII cells to facilitate the investigation of compound absorption across relevant barriers. This aids in determining a compound’s suitability for oral dosing, a critical step in drug development.
Analysing the permeability of compounds across a cell monolayer is a widely recognised in vitro method for assessing oral absorption and investigating transport mechanisms. The range of pre-plated transwell products ensures rapid and accurate determination of drug transport across Caco-2, HT-29, and MDCKII cell monolayers.
Blood Brain Barrier (BBB) Assays
ReadyCell’s Blood Brain Barrier (BBB) Assays enable researchers to conduct a thorough assessment of the permeability and intricate transporter-drug interactions. The kits offer a valuable tool to assist researchers in determining the suitability of their compounds for BBB traversal.
To gain insights into the pharmacological route and enhance clinical stages, it is recommended to assess the interaction of in-development molecules with P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) receptors. ReadyCell’s suite of assay-based plates, including CacoReady, PreadyPort MDR1, and PreadyPort BCRP, facilitates the identification of whether new molecular entities serve as substrates or inhibitors of MDR1 or BCRP, thereby aiding in the refinement of drug candidates.
In Vitro Cytotoxicity Assays
ReadyCell’s innovative ready-to-use cell-based plates offer a superior alternative to traditional colorimetric assays. The CacoReady plates enable the identification of potential toxicity at early research stages. Utilising CacoReady researchers can accurately predict and stratify intestinal compound toxicity by evaluating the transepithelial electrical resistance (TEER) value and the lucifer yellow (LY) paracellular flux, two crucial indicators of cell barrier integrity.
CacoReady is a pre-plated transwell product that contains Caco-2 cells, which are human intestinal epithelial cells. Since Caco-2 cells resemble the human intestinal epithelium more closely than other cell lines or animal models, it provides a more relevant and reliable model for intestinal drug studies. Short-term cytotoxicity tests frequently yield positive results that correlate effectively with short-term in vivo implantation tests. Therefore, utilising CacoReady can reduce the need for animal testing, lowers costs, and speeds up the development of new drugs.
Moreover, for traditional studies, ReadyCell also offers plates without transwell inserts, catering to a wider range of research needs and methodologies.
Transporter Kits for Drug-Drug Interactions (DDI) Studies
ReadyCell offers a range of ready-to-use Efflux Transporter Kits and Uptake Transporter Plates that are indispensable tools for studying drug-drug interactions (DDI) and optimising drug discovery screening. They offer a highly predictive in vitro model, aligning with FDA and EMA guidelines for robust DDI assessment.
Ready to use Efflux Transporter Plates
The PreadyPort MDR1 Transporter Expression Plates incorporate the multidrug resistance protein 1 (MDR1) or P-glycoprotein (P-gp). MDR1 is a crucial efflux transporter impacting drug metabolism and excretion.
The PreadyPort BCRP Kit, featuring MDCKII cells with ABCG2 gene transfection, enables the overexpression of the clinically significant breast cancer resistance protein (BCRP). BCRP actively extricates substances from cells, influencing drug absorption and distribution.
Uptake Transporter Plates
ReadyCell’s Uptake Transporter Plates are designed to enhance DDI studies and support clinical investigations. These plates contain crucial membrane proteins influencing ADME, such as:
PreadyTake MATE1 contains HEK293 cells transfected with the SLC47A1 gene to overexpress the drug and toxin transporter-1 (MATE1), a membrane transporter of clinical importance for assessing drug-transporter interactions at preclinical stages.
PreadyTake OCT2 features HEK293 cells transfected with the SLC22A2 gene to overexpress organic cation transporter-2 (OCT2), a primarily renal uptake transporter expressed on the basolateral (blood) side of proximal tubule cells.
PreadyTake OATP1B3 comprises HEK293 cells transfected with the SLCO1B3 gene to overexpress the organic anion-transporting polypeptide 1B3 (OATP1B3), a membrane transporter of considerable clinical importance. This allows for the evaluation of drug-transporter interactions in preclinical stages.
About ReadyCell
ReadyCell is a leading biotechnology company delivering innovative rapidly deployable cell-based in vitro products and tools that accelerate drug discovery.
The company’s groundbreaking cell-based ready-to-use ADME-Tox kits are utilised by leading pharmaceutical, biotechnology, academic, and contract research organisations worldwide to optimise the development cycle for new drugs.
With more than a decade of experience, ReadyCell has developed a revolutionary medium for the transportation of live plated cells preserving their full viability and cellular attributes, to ensure highly reliable results whilst improving time and cost efficiency.
Headquartered at Barcelona Science Park, ReadyCell has established a wide distribution network enabling researchers and scientists around the world to access the most innovative tools for all their in vitro ADME-Tox, DMPK, and DDI studies.
ProductsReady-to-use HEK293 Cell-based In Vitro Plates
ReadyCell has developed an advanced range of ready-to-use HEK293 Cell-based In Vitro Plates for studying uptake drug-transporter interactions in preclinical …
Read MoreMDCKII Cell-based Plates for In Vitro Drug-transporter Studies
ReadyCell has developed an advanced range of MDCKII Cell-based Plates for In Vitro Drug-transporter Studies in preclinical testing and drug …
Read MoreCaco-2 and HT-29 Co-culture Intestinal Absorption Cell-based Plates
The Caco-2 and HT-29 Co-culture Intestinal Absorption cell-based plates are a ready-to-use in vitro cell-based model for intestinal absorption evaluation …
Read MoreCaco-2 Permeability Cell-based Plates
The Caco-2 Permeability Cell-based Plates offer a ready-to-use solution for evaluating the in vitro intestinal absorption of drug targets. The …
Read MoreDownloadsThe Role of Kidney Transporters in Decoding Renal Drug Elimination
Renal elimination of drugs: The role of kidney transporters A ReadyCell .pdf White Paper – Author: Lourdes Gombau, R&D Director …
Read MoreA Game-Changer in Predicting Drug-Induced Gastrointestinal Toxicity
CacoReady, a Useful Cell Model to Predict Drug-Induced Gastrointestinal Toxicity A ReadyCell .pdf Case Study – Author: Marta Olle Monge, …
Read MoreVideosPre-plated Cell-based Assays for Drug Discovery – Video
ReadyCell’s cutting-edge pre-plated cell-based assays are developed to accelerate and streamline drug discovery and development studies. The Benefits of Utilising …
Read MorePress ReleasesInnovative Gel-Like Medium Revolutionises Long-Distance Cell Transportation
In vitro mammalian cells such as Caco-2 or MDCKII, crucial for preclinical research and drug discovery, are highly challenging to …
Read MoreEncouraging Outcomes for Novel Therapy Targeting Drug-resistant Tuberculosis
Researchers have made a significant leap forward in the fight against drug-resistant tuberculosis (TB), according to a recent study published …
Read MoreChoosing the Right Well Plate Format for Your Research
Choosing the most appropriate well system format, whether it’s a transwell, non-transwell, or individual transwell, can drastically affect the outcome …
Read MoreCacoReady Plates Aid Discovery of Novel HDAC Inhibitors for Prostate Cancer
Cutting-edge CacoReady Cell-based Plates with pre-developed Caco-2 cells for in vitro permeability assessment have been a key tool in a …
Read MoreContactReadyCell S.L.
Barcelona Science Park
Carrer de Baldiri Reixac 10
08028 Barcelona
SpainPhone: +34 934 037 077